JZJianlong Zhou

Jianlong Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jianlong Zhou has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Qiongqian Li

    Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, Guangxi, China

    3 shared publications
  • Tongze Cai

    Guangxi International Zhuang Medicine Hospital Guangxi University of Chinese Medicine Nanning 530200 China

    3 shared publications
  • Juanmei Mo

    Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, Guangxi, China

    2 shared publications
  • Shunrong Zhang

    Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, Guangxi, China

    2 shared publications
  • Bao Xiao

    School of Medicine Southern University of Science and Technology Shenzhen 518055 China

    1 shared publication
  • Caiyue Lin

    Graduate School, Guangxi University of Chinese Medicine, Nanning, China

    1 shared publication

Latest Publications

  • Open Access

    Targeting macrophage glycolytic–serine metabolism and NF–κB activation by compound Xiancao granule confers renoprotection in diabetic nephropathy

    by Shunrong Zhang, Shan Chen, Zhichuan Gan, Longlong Wang, Qiongqian Li, Xiaohua Huang, Wenhao Zhao, Yuxuan Zhu, Yesheng Liang, Yifan Gu, et al.

  • Inhibition of the m6A Reader IGF2BP2 Impairs Cell Cycle Progression and Glycolysis in Ovarian Cancer

    by J. Liang, X. Yang, K. Ji, G. Zhu, J. Wang, H. Duan, J. Zhou, Z. Qin

    N6-methyladenosine (m6A) is the most abundant internal RNA modification in eukaryotic mRNAs and plays a crucial role in regulating mRNA stability, translation, and degradation. Dysregulation of m6A regulators has been increasingly implicated in cancer, yet their cell type–specific roles and therapeutic value in ovarian cancer remain clearly unexplored. We conducted an integrative analysis of single-cell and bulk RNA sequencing datasets from ovarian tumors and matched non-malignant tissues to identify m6A regulators associated with tumor progression. Functional experiments, including gene knockdown, flow cytometry, metabolic assays, and RIP-seq analysis, were performed to evaluate the role of candidate regulators. A small-molecule inhibitor of IGF2BP2 (CWI1-2) was also used to assess therapeutic potential in ovarian cancer cell lines. IGF2BP2 was identified as the most significantly upregulated m6A reader in malignant epithelial cells and was associated with poor patient prognosis. Knockdown of IGF2BP2 impaired cell proliferation, induced cell cycle arrest and apoptosis, and suppressed glycolytic activity. RIP-seq data revealed that IGF2BP2 directly binds transcripts of key oncogenes including CDK4, BCL2L2, and SLC2A1, thereby stabilizing their expression. Pharmacological inhibition of IGF2BP2 recapitulated the effects of genetic silencing, confirming its essential role in sustaining oncogenic programs in ovarian cancer cells. Our findings establish IGF2BP2 as a critical m6A reader that post-transcriptionally regulates gene networks driving proliferation, survival, and metabolic reprogramming in ovarian cancer. Targeting IGF2BP2 may represent a promising therapeutic strategy for m6A-based precision oncology in ovarian cancer.

  • Open Access

    Localized Delivery of the mRNAs Encoding CD47 Inhibitor and Interleukins 12, 15, and 21 Elicits Robust Antitumor Immunity

    by Tao Jiang, Shuaiyang Jing, Haojun Li, Bao Xiao, Jiahui Jin, Xiu Sun, Juan Wang, Jing Liang, Tongze Cai, Huili Hu, et al.

    CD47 inhibitors have emerged as promising candidates in cancer immunotherapy by activating macrophage phagocytosis through CD47/SIRPα signal blockade and enhancing dendritic cell antigen presentation. However, their clinical efficacy remains limited and is accompanied by severe side effects, including anemia and hemagglutination. To address these limitations, a localized delivery strategy is developed using lipid nanoparticles to encapsulate mRNA encoding a secreted CD47 inhibitor. This mRNA‐derived CD47 inhibitor effectively activated macrophages against cancer cells in vitro. To improve its modest tumor‐suppressive effects in vivo, a combination therapy is formulated by co‐delivering mRNAs encoding the CD47 inhibitor and a cytokine cocktail (interleukins 12, 15, and 21), achieving synergistic antitumor effects. Notably, this strategy induces robust systemic antitumor immunity and long‐lasting immunological memory, effectively suppressing metastatic tumor progression following localized treatment of the primary tumor. Mechanistically, the mRNA‐derived CD47 inhibitor promoted the differentiation of conventional type 1 dendritic cells, facilitating T cell cross‐priming and activating cytotoxic T cells. Additionally, the cytokine cocktail further augmented the antitumor activity of these cytotoxic T cells. These findings present a promising strategy for advancing clinical cancer treatment, addressing key challenges associated with current CD47 inhibitor therapies.


  • Open Access

    Efficacy and safety of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma: a systematic review and network meta-analysis

    by Tongze Cai, Caiyue Lin, Qiongqian Li, Juanmei Mo, Jinghui Zheng, Jianlong Zhou

    Background: To compare the efficacy and safety of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).Methods: We searched databases, including PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and major international conferences, to identify comparative randomized controlled trials (RCTs) for the first-line treatment of patients with nasopharyngeal carcinoma who have metastasis or recurrence from inception to March 1, 2024. Then, we conducted a Bayesian network meta-analysis and systematic review of RCTs that met the specified inclusion criteria. By calculating the surface under the cumulative ranking curve (SUCRA) for each treatment, we determined their relative advantage: the higher the SUCRA score, the more likely that treatment is to be the optimal choice.Results: Seven RCTs were included, which involved 1495 patients who received 8 different treatment regimens. Overall, programmed cell death protein 1 (PD-1) inhibitors combined with chemotherapy could be the optimal treatment for patients with RM-NPC. Chemotherapy combined with radiotherapy has a tendency to improve progression-free survival and overall survival. The safety assessment showed no significant difference in the incidence of grade 3 or higher adverse events between any two treatments. Tislelizumab, combined with the standard first-line chemotherapy regimen, appeared to confer the best progression-free survival (SUCRA = 83.16%), overall survival (SUCRA = 83.16%), and objective response rate (SUCRA = 89%).Conclusions: Systematic reviews and network meta-analyses integrate evidence from multiple studies, which enables clinicians to make more informed treatment decisions based on comprehensive comparative efficacy and safety data. For patients with RM-NPC, the combination of tislelizumab and chemotherapy is the optimal first-line treatment.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42023491570, identifier CRD42023491570.


  • Open Access

    EML4‐ALK‐Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review

    by Qiongqian Li, Tongze Cai, Xiaoming Zheng, Shunrong Zhang, Chanjuan Li, Huang Tang, Zhiyong Yu, Jianlong Zhou

    We report a case showing that lorlatinib is effective in treating EML4‐ALK‐positive low‐grade serous ovarian cancer (LGSO) with intracranial metastasis. This may be the first clinical evidence of LGSO benefit from ALK inhibitors, to provide evidence for the use of ALK inhibitors in more ovarian cancer patients with EML4‐ALK fusion and promoting new ideas for the study of EML4‐ALK targets in ovarian cancer.